Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADMTNASDAQ:BTCYNASDAQ:VVOSNASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMTADM Tronics Unlimited$0.06$0.07$0.03▼$0.11$3.81M-0.0217,344 shs15 shsBTCYBiotricity$0.58+12.6%$0.45$0.19▼$1.09$14.39M1.2235,483 shs66,573 shsVVOSVivos Therapeutics$2.21-5.8%$2.50$1.97▼$6.28$13.02M7.02455,935 shs71,913 shsXAIRBeyond Air$0.18-2.7%$0.21$0.16▼$1.49$15.72M0.251.24 million shs1.18 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMTADM Tronics Unlimited+0.04%+18.07%-6.91%-19.54%-19.77%BTCYBiotricity+8.11%+2.62%+4.29%-1.86%-50.18%VVOSVivos Therapeutics-0.85%+2.18%-10.34%-37.10%+7.83%XAIRBeyond Air+0.11%-1.05%-9.62%-28.71%-84.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMTADM Tronics UnlimitedN/AN/AN/AN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/AN/AN/AN/AVVOSVivos Therapeutics2.3469 of 5 stars3.35.00.00.02.00.00.6XAIRBeyond Air4.2955 of 5 stars3.53.00.03.52.22.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMTADM Tronics Unlimited 0.00N/AN/AN/ABTCYBiotricity 2.00HoldN/AN/AVVOSVivos Therapeutics 2.50Moderate Buy$4.82118.44% UpsideXAIRBeyond Air 3.00Buy$1.50719.67% UpsideCurrent Analyst Ratings BreakdownLatest ADMT, XAIR, VVOS, and BTCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/15/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.204/1/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMTADM Tronics Unlimited$2.96M1.29N/AN/AN/A∞BTCYBiotricity$12.06M1.19N/AN/A($1.30) per share-0.44VVOSVivos Therapeutics$14.63M0.89N/AN/A$0.22 per share10.02XAIRBeyond Air$3.02M5.23N/AN/A$0.27 per share0.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMTADM Tronics Unlimited-$880KN/A0.00∞N/A-13.47%-49.27%-18.74%7/14/2025 (Estimated)BTCYBiotricity-$14.09M-$1.08N/A∞N/A-80.42%N/A-188.47%6/25/2025 (Estimated)VVOSVivos Therapeutics-$13.58M-$1.73N/AN/AN/A-86.19%-335.04%-93.58%8/13/2025 (Estimated)XAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,730.00%-226.01%-109.75%6/17/2025 (Estimated)Latest ADMT, XAIR, VVOS, and BTCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/25/2025N/ABTCYBiotricity-$0.10N/AN/AN/A$3.60 millionN/A6/17/2025Q4 2025XAIRBeyond Air-$0.14N/AN/AN/A$1.39 millionN/A5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million3/27/2025Q4 2024VVOSVivos Therapeutics-$0.43-$0.28+$0.15-$0.28$3.89 million$3.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMTADM Tronics UnlimitedN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMTADM Tronics UnlimitedN/A1.210.78BTCYBiotricityN/A0.230.10VVOSVivos TherapeuticsN/A1.441.44XAIRBeyond AirN/A3.563.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMTADM Tronics UnlimitedN/ABTCYBiotricity3.89%VVOSVivos Therapeutics26.35%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipADMTADM Tronics Unlimited73.00%BTCYBiotricity10.10%VVOSVivos Therapeutics3.00%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMTADM Tronics Unlimited2367.59 million18.25 millionNot OptionableBTCYBiotricity4024.91 million22.08 millionOptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableXAIRBeyond Air7086.37 million54.97 millionOptionableADMT, XAIR, VVOS, and BTCY HeadlinesRecent News About These CompaniesBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3 at 5:08 PM | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comBeyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric OxideApril 25, 2025 | msn.comBeyond Air, Inc. Secures U.S. Patent for Novel Nitric Oxide Delivery Method in Treating NTM Lung InfectionsApril 24, 2025 | quiverquant.comBeyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 23, 2025 | finanznachrichten.deNeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 21, 2025 | globenewswire.comNeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory BoardApril 15, 2025 | globenewswire.comBeyond Air subsidiary granted orphan designation for Phelan-McDermid treatmentApril 15, 2025 | markets.businessinsider.comJonesTrading Sticks to Their Buy Rating for Beyond Air (XAIR)April 15, 2025 | markets.businessinsider.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air subsidiary NeuroNOS announces publication of researchApril 2, 2025 | markets.businessinsider.comBeyond Air announces VUMC as first luminary siteApril 1, 2025 | markets.businessinsider.comBeyond Air Announces Vanderbilt University Medical Center as First Luminary SiteMarch 31, 2025 | globenewswire.comNeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism TherapyMarch 24, 2025 | globenewswire.comBeyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADMT, XAIR, VVOS, and BTCY Company DescriptionsADM Tronics Unlimited OTCMKTS:ADMT$0.06 0.00 (0.00%) As of 06/4/2025ADM Tronics Unlimited, Inc., through its subsidiaries, develops, manufactures, and sells electronics for non-invasive medical and other applications in the United States, Australia, Asia, and Europe. It operates through Chemical, Electronics, and Engineering segments. The company offers proprietary devices for use in diagnostics and therapeutics of humans and animals; and electronic controllers for spas and hot tubs. In addition, the company provides water-based primers and adhesives; water-based coatings and resins; water-based chemical additives; and anti-static conductive paints, coatings, and other products. Further, it offers water-based, adhesive and related topical formulations for use in maxillofacial prosthetic medical applications; and for professional makeup applications primarily for film, TV, and theatrical productions. Additionally, the company provides research, development, regulatory, and engineering services for the design, development, and manufacturing of medical devices, electronics, and other technologies and products, as well as medical electronic therapeutic technology. ADM Tronics Unlimited, Inc. was incorporated in 1969 and is headquartered in Northvale, New Jersey.Biotricity NASDAQ:BTCY$0.58 +0.06 (+12.55%) As of 03:08 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Vivos Therapeutics NASDAQ:VVOS$2.20 -0.14 (-5.77%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Beyond Air NASDAQ:XAIR$0.18 -0.01 (-2.66%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
